Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Endovascular abdominal and thoracic aortic repair. Main billing specialty: vascular surgery.
Medicare fee-for-service aortic endografts (EVAR/TEVAR) cases in the 34 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (139 state-years, 2020–2024): read it as a direction with a margin.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 10 | 1,226−4.3%/yr | −4.3%/yr | 0.61.2× | 0% | 1,210 in 2030−0.2%/yr |
| Texas | 3 | 1,065−5.8%/yr | −5.8%/yr | 0.51.1× | 0% | 1,150 in 2030+1.3%/yr |
| California | 6 | 979−4.9%/yr | −4.9%/yr | 0.30.7× | 0% | 1,400 in 2030+6.1%/yr |
| New York | 7 | 818−5.7%/yr | −5.7%/yr | 0.51.0× | 0% | 860 in 2030+0.8%/yr |
| Pennsylvania | 1 | 705−5.5%/yr | −5.5%/yr | 0.51.2× | 0% | 710 in 2030+0.1%/yr |
| Ohio | 3 | 615−5.9%/yr | −5.9%/yr | 0.61.3× | 0% | 460 in 2030−4.8%/yr |
| Illinois | 7 | 563−7.4%/yr | −7.4%/yr | 0.40.9× | 0% | 600 in 2030+1.1%/yr |
| North Carolina | 3 | 449−8.3%/yr | −8.3%/yr | 0.51.0× | 0% | 420 in 2030−1.1%/yr |
| Virginia | 3 | 443−6.2%/yr | −6.2%/yr | 0.41.0× | 0% | 440 in 2030−0.2%/yr |
| Georgia | 2 | 405−5.4%/yr | −5.4%/yr | 0.51.1× | 0% | 450 in 2030+1.8%/yr |
| New Jersey | 3 | 400−7.7%/yr | −7.7%/yr | 0.40.9× | 0% | 360 in 2030−1.6%/yr |
| Michigan | 0 | 381−11%/yr | −11%/yr | 0.51.0× | 0% | 370 in 2030−0.6%/yr |
| Missouri | 5 | 372−9.1%/yr | −9.1%/yr | 0.61.4× | 0% | 340 in 2030−1.6%/yr |
| Indiana | 4 | 350−7.1%/yr | −7.1%/yr | 0.51.1× | 0% | 380 in 2030+1.5%/yr |
| Massachusetts | 1 | 350−5.5%/yr | −5.5%/yr | 0.40.8× | 0% | 390 in 2030+1.8%/yr |
| Tennessee | 2 | 345−9.6%/yr | −9.6%/yr | 0.51.1× | 0% | 400 in 2030+2.4%/yr |
| Maryland | 2 | 330−2.9%/yr | −2.9%/yr | 0.40.8× | 0% | 400 in 2030+3.3%/yr |
| Arizona | 3 | 322−6.9%/yr | −6.9%/yr | 0.41.0× | 0% | 370 in 2030+2.5%/yr |
| Washington | 3 | 302−6.6%/yr | −6.6%/yr | 0.40.9× | 0% | 230 in 2030−4.4%/yr |
| Kentucky | 2 | 285−10%/yr | −10%/yr | 0.61.4× | 0% | 280 in 2030−0.3%/yr |
| South Carolina | 0 | 274−8.3%/yr | −8.3%/yr | 0.40.9× | 0% | 250 in 2030−1.7%/yr |
| Alabama | 2 | 218−11%/yr | −11%/yr | 0.51.1× | 0% | 230 in 2030+1%/yr |
| Arkansas | 6 | 201−3.4%/yr | −3.4%/yr | 0.51.2× | 0% | 170 in 2030−3.1%/yr |
| Wisconsin | 1 | 197−8.5%/yr | −8.5%/yr | 0.40.8× | 0% | 270 in 2030+5.7%/yr |
| Minnesota | 0 | 187−8.9%/yr | −8.9%/yr | 0.40.9× | 0% | 190 in 2030+0.2%/yr |
| Kansas | 3 | 178−7.8%/yr | −7.8%/yr | 0.41.0× | 0% | 160 in 2030−1.9%/yr |
| Colorado | 0 | 174−6.8%/yr | −6.8%/yr | 0.40.8× | 0% | 200 in 2030+2.7%/yr |
| Iowa | 1 | 169+0.7%/yr | +0.7%/yr | 0.40.9× | 0% | 210 in 2030+3.4%/yr |
| Oregon | 0 | 169−9.9%/yr | −9.9%/yr | 0.40.9× | 0% | 170 in 2030−0.3%/yr |
| Louisiana | 0 | 167−8.5%/yr | −8.5%/yr | 0.40.9× | 0% | 140 in 2030−2.8%/yr |
| Oklahoma | 3 | 167−14%/yr | −14%/yr | 0.30.8× | 0% | 190 in 2030+2.3%/yr |
| Connecticut | 1 | 160−6.4%/yr | −6.4%/yr | 0.51.1× | 0% | 150 in 2030−0.8%/yr |
| Mississippi | 2 | 121−7.9%/yr | −7.9%/yr | 0.30.7× | 0% | 130 in 2030+1.1%/yr |
| Nevada | 0 | 117−8%/yr | −8%/yr | 0.40.9× | 0% | 100 in 2030−2.4%/yr |
Professional codes (what the surgeon bills): CPT 34701, 34702, 34703, 34704, 34705, 34706, 33880, 33881; the hospital bills MS-DRG 268, 269, 213, 209.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 454 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 7 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| W L Gore & Associates | 172 |
| Medtronic | 120 |
| Terumo | 68 |
| Cook | 51 |
| Endologix | 30 |
| Cordis | 12 |
| Lombard Medical | 1 |
Product codes: MIH (system, endovascular graft, aortic aneurysm treatment). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 100% of the cases CMS names in Florida; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Peripheral arterial intervention | 1,321 | 182,726−5.9%/yr | −5.9%/yr | 215,300 in 2030+2.8%/yr |
| Superficial venous ablation | 1,980 | 166,794−4.1%/yr | −4.1%/yr | 191,600 in 2030+2.3%/yr |
| Dialysis access | 1,721 | 161,268−13%/yr | −13%/yr | 158,700 in 2030−0.3%/yr |
| Thrombectomy, IVC filters & venous stents | 389 | 47,332+0.1%/yr | +0.1%/yr | 62,700 in 2030+4.8%/yr |
| Carotid revascularization | 741 | 36,694−5%/yr | −5%/yr | 40,000 in 2030+1.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 7 companies reported engagement with surgeons in the covered states worth $5.4M in consulting, speaking, meals and travel tied to these products, about $60K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 36 clearances and approvals in the category, 2 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.